Revvity Inc (RVTY)

$97.62 +0.50 (0.51%)
Market Cap 11.01B
Revenue (ttm) 2.86B
Net Income (ttm) 241.20M
EPS (ttm) N/A
PE Ratio 19.79
Forward PE 18.53
Profit Margin 8.45%
Debt to Equity Ratio 0.44
Volume 705,500
Avg Vol 1,391,896
Day's Range N/A - N/A
Shares Out 113.38M
Stochastic %K 36%
Beta 1.06
Analysts Sell
Price Target $119.40

Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and sc...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 663 6900
Address:
77 4th Avenue, Waltham, United States
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 25 at 3:13 PM
$RVTY This was at $118 before the ER which was a beat and raise then the CEO who is hard to understand and the CFO who screams opened their mouths …. When is the BOD going to get rid of these clowns?
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 24 at 3:55 PM
$RVTY This has been thrown into the “sell the software “ story which is nonsense 3 conferences coming up start loading
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 17 at 5:43 PM
$RVTY This one has been a disaster for me Down now 24 points since they reported a BEAT and RAISE both revenue and eps Don’t know if it’s being dumped into the “software” sell
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 17 at 2:20 PM
$RVTY 3 conference’s coming up ….
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 12 at 4:00 PM
$RVTY Down over 20% since earnings which btw were VG They have great products and a fortress balance sheet The CEO and CFO need to go the messaging is awful
0 · Reply
Estimize
Estimize Feb. 11 at 3:03 PM
Wall St is expecting 1.03 EPS for $RVTY Q1 [Reporting 05/04 BMO] http://www.estimize.com/intro/rvty?chart=historical&metric_name=eps&utm_co
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 6 at 3:43 PM
$RVTY Time to go all in
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 5 at 6:13 PM
$RVTY Share Price: $99.92 Contract Selected: Sep 18, 2026 $100 Calls Buy Zone: $10.79 – $13.33 Target Zone: $18.72 – $22.88 Potential Upside: 64% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
koditrump
koditrump Feb. 4 at 3:56 PM
$OLN $TSLA $RVTY $RIVN
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 4 at 2:32 PM
$RVTY It doesn’t get any more bullish
0 · Reply
Latest News on RVTY
Revvity to Present at Upcoming Investor Conferences

Feb 17, 2026, 8:00 AM EST - 8 days ago

Revvity to Present at Upcoming Investor Conferences

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Feb 5, 2026, 8:00 AM EST - 20 days ago

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Revvity: Close To A Buy, Not Quite There

Feb 3, 2026, 1:35 PM EST - 21 days ago

Revvity: Close To A Buy, Not Quite There

Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results

Feb 3, 2026, 9:20 AM EST - 22 days ago

Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results

Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript

Feb 2, 2026, 12:30 PM EST - 22 days ago

Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript

Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Feb 2, 2026, 10:28 AM EST - 23 days ago

Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Feb 2, 2026, 7:13 AM EST - 23 days ago

Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

Feb 2, 2026, 6:00 AM EST - 23 days ago

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

Revvity Board Declares Quarterly Dividend

Jan 26, 2026, 4:05 PM EST - 4 weeks ago

Revvity Board Declares Quarterly Dividend

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

Jan 21, 2026, 1:33 PM EST - 4 weeks ago

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

BIO CABO CDW CNC EXPE FCNCA LKQ

Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:56 PM EST - 6 weeks ago

Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Jan 13, 2026, 5:51 AM EST - 6 weeks ago

Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.

Revvity says it will exceed 2025 profit forecast range

Jan 12, 2026, 5:10 PM EST - 6 weeks ago

Revvity says it will exceed 2025 profit forecast range

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Jan 12, 2026, 4:15 PM EST - 6 weeks ago

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Jan 9, 2026, 8:00 AM EST - 6 weeks ago

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Revvity to Present at J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 2 months ago

Revvity to Present at J.P. Morgan Healthcare Conference

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Dec 16, 2025, 8:00 AM EST - 2 months ago

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 12:53 PM EST - 3 months ago

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 11:38 AM EST - 3 months ago

Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 10:11 AM EST - 3 months ago

Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Nov 10, 2025, 8:00 AM EST - 3 months ago

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Nov 10, 2025, 7:45 AM EST - 3 months ago

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Oct 28, 2025, 9:32 AM EDT - 4 months ago

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Revvity: Software Momentum And Screening Offset China Weakness

Oct 27, 2025, 12:56 PM EDT - 4 months ago

Revvity: Software Momentum And Screening Offset China Weakness

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 12:47 PM EDT - 4 months ago

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Oct 27, 2025, 7:06 AM EDT - 4 months ago

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Revvity Announces Financial Results for the Third Quarter of 2025

Oct 27, 2025, 6:00 AM EDT - 4 months ago

Revvity Announces Financial Results for the Third Quarter of 2025

Revvity Showcases Progress with Purpose in 2025 Impact Report

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Revvity Showcases Progress with Purpose in 2025 Impact Report

Revvity to Hold Earnings Call on Monday, October 27, 2025

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Revvity to Hold Earnings Call on Monday, October 27, 2025

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

Oct 2, 2025, 8:00 AM EDT - 5 months ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

SNY

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Sep 29, 2025, 8:00 AM EDT - 5 months ago

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Sep 22, 2025, 8:00 AM EDT - 5 months ago

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 9, 2025, 5:31 PM EDT - 6 months ago

Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 10:40 AM EDT - 6 months ago

Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Aug 6, 2025, 8:00 AM EDT - 7 months ago

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Jul 28, 2025, 2:47 PM EDT - 7 months ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Jul 28, 2025, 1:40 PM EDT - 7 months ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

Jul 28, 2025, 12:25 PM EDT - 7 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

LNG NKE

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 11:59 AM EDT - 7 months ago

Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Jul 28, 2025, 8:13 AM EDT - 7 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ATAI

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Jul 28, 2025, 8:09 AM EDT - 7 months ago

Revvity trims 2025 profit forecast on soft demand for diagnostics in China

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Jul 28, 2025, 7:39 AM EDT - 7 months ago

Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.

Revvity Announces Financial Results for the Second Quarter of 2025

Jul 28, 2025, 6:00 AM EDT - 7 months ago

Revvity Announces Financial Results for the Second Quarter of 2025

Revvity to Hold Earnings Call on Monday, July 28, 2025

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Revvity to Hold Earnings Call on Monday, July 28, 2025

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 19, 2025, 8:00 AM EDT - 10 months ago

Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

May 9, 2025, 10:35 AM EDT - 10 months ago

Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 11:49 AM EDT - 10 months ago

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Apr 28, 2025, 9:14 AM EDT - 10 months ago

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 25 at 3:13 PM
$RVTY This was at $118 before the ER which was a beat and raise then the CEO who is hard to understand and the CFO who screams opened their mouths …. When is the BOD going to get rid of these clowns?
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 24 at 3:55 PM
$RVTY This has been thrown into the “sell the software “ story which is nonsense 3 conferences coming up start loading
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 17 at 5:43 PM
$RVTY This one has been a disaster for me Down now 24 points since they reported a BEAT and RAISE both revenue and eps Don’t know if it’s being dumped into the “software” sell
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 17 at 2:20 PM
$RVTY 3 conference’s coming up ….
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 12 at 4:00 PM
$RVTY Down over 20% since earnings which btw were VG They have great products and a fortress balance sheet The CEO and CFO need to go the messaging is awful
0 · Reply
Estimize
Estimize Feb. 11 at 3:03 PM
Wall St is expecting 1.03 EPS for $RVTY Q1 [Reporting 05/04 BMO] http://www.estimize.com/intro/rvty?chart=historical&metric_name=eps&utm_co
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 6 at 3:43 PM
$RVTY Time to go all in
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 5 at 6:13 PM
$RVTY Share Price: $99.92 Contract Selected: Sep 18, 2026 $100 Calls Buy Zone: $10.79 – $13.33 Target Zone: $18.72 – $22.88 Potential Upside: 64% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
koditrump
koditrump Feb. 4 at 3:56 PM
$OLN $TSLA $RVTY $RIVN
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 4 at 2:32 PM
$RVTY It doesn’t get any more bullish
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 3 at 4:50 PM
$RVTY Time to re load
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 3 at 4:09 PM
$RVTY Major acquisition target …..
0 · Reply
erevnon
erevnon Feb. 3 at 2:40 PM
Wells Fargo maintains Revvity $RVTY at Equal-Weight and raises the price target from $107 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Feb. 3 at 1:53 PM
Barclays maintains Revvity $RVTY at Overweight and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Feb. 3 at 1:26 PM
Jefferies maintains Revvity $RVTY at Hold and raises the price target from $100 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Feb. 2 at 5:16 PM
$RVTY: Revvity (-4%) delivered a clean quarter with upside across EPS, diagnostics strength, and above-consensus 2026 guidance. Despite the market's near-term uncertainty, improving Life Sciences trends and aggressive buybacks point to a more focused growth story. Get all the details here: https://www.briefing.com/story-stocks/archive/2026/2/2/revvity-finds-its-rhythm-eps-upside-diagnostics-strength-and-a-leaner-growth-story-(rvty)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 2 at 5:12 PM
$RVTY $120 short term PT
0 · Reply
ZacksResearch
ZacksResearch Feb. 2 at 4:32 PM
$RVTY beats EPS estimates, but revenue was in line with expectations. 🤔 Revvity's Q4 EPS of $1.70 topped the Zacks Consensus Estimate by 4.3%, while revenue was just in line at $772.1M. A mixed bag as shares gain 2.5% pre-market. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2827085/revvity-stock-up-as-q4-earnings-beat-revenues-in-line-with-estimates?cid=sm-stocktwits-2-2827085-body-31489&ADID=SYND_STOCKTWITS_TWEET_2_2827085_BODY_31489
0 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Feb. 2 at 3:44 PM
$RVTY Blowout Q and raised guidance Time to add heavy
0 · Reply
ZacksResearch
ZacksResearch Feb. 2 at 3:32 PM
$RVTY jumps after a clean Q4 beat — earnings power showing up 📊 Q4 adjusted EPS of $1.70 topped estimates, while revenue improved 5.9% to $772.1 million and came in line with expectations — a solid combo that got the stock moving. What this earnings beat really signals for the stock 👉 https://www.zacks.com/stock/news/2827085/revvity-stock-up-as-q4-earnings-beat-revenues-in-line-with-estimates?cid=sm-stocktwits-2-2827085-teaser-31478&ADID=SYND_STOCKTWITS_TWEET_2_2827085_TEASER_31478
0 · Reply
1986iamwallstreet
1986iamwallstreet Feb. 2 at 2:26 PM
$RVTY Guidance still screams “cautious / not confident the rebound is real” 🩸🩸🩸🩸🩸
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 2 at 1:44 PM
$RVTY (-1.7% pre) Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025 https://ooc.bz/l/91580
0 · Reply